Autophagic and apoptotic effects of HDAC inhibitors on cancer cells

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic alterations, including histone deacetylase (HDAC) activity, are implicated in cancer development by affecting tumor suppressor genes.
• Histone deacetylase inhibitors (HDACis) are being investigated as a therapeutic strategy for various cancers.
• HDACis can induce apoptosis and autophagy, cellular processes linked to anticancer effects.

Purpose of the Study:

• To critically discuss the anticancer potential of HDAC inhibitors.
• To explore how HDAC inhibitors elicit anti-tumor responses through different cell death pathways.
• To highlight autophagy activation as a novel cancer treatment target.

Main Methods:

• Literature review and critical discussion of existing preclinical and clinical data on HDAC inhibitors in cancer therapy.
• Analysis of the mechanisms by which HDAC inhibitors induce apoptosis and autophagy.
• Evaluation of alternative cell death pathways targeted by HDAC inhibitors.

Main Results:

• HDAC inhibitors demonstrate anticancer activity through the induction of apoptosis and autophagy in various cancer cell lines.
• Cancer cells often exhibit resistance to apoptosis, making alternative cell death pathways crucial for therapy.
• Autophagy activation presents a promising target for enhancing the efficacy of anti-cancer treatments.

Conclusions:

• HDAC inhibitors represent an attractive therapeutic approach for cancer due to their ability to modulate epigenetic modifications.
• The induction of both apoptosis and autophagy by HDAC inhibitors contributes to their anticancer potential.
• Targeting alternative pathways like autophagy is essential for overcoming cancer's inherent resistance and improving therapeutic outcomes.